153 related articles for article (PubMed ID: 11913472)
21. [Clinical efficacy of myocardial cytoprotector trimetazidine in peri- and postmenopausal women with ischemic heart disease].
Churshin AD; Pimenov LT
Kardiologiia; 2003; 43(8):31-5. PubMed ID: 14593380
[TBL] [Abstract][Full Text] [Related]
22. Trimetazidine and the contractile response of dysfunctional myocardium in ischaemic cardiomyopathy.
Belardinelli R
Rev Port Cardiol; 2000 Nov; 19 Suppl 5():V35-9. PubMed ID: 11206102
[TBL] [Abstract][Full Text] [Related]
23. Cardioprotective effects of trimetazidine and a combination of succinic and malic acids in acute myocardial ischemia.
Khazanov VA; Kiseliova AA; Vasiliev KY; Chernyschova GA
Bull Exp Biol Med; 2008 Aug; 146(2):218-22. PubMed ID: 19145322
[TBL] [Abstract][Full Text] [Related]
24. [Potentialities of cytoprotection in the treatment of chronic heart failure in patients with coronary heart disease].
Fedorova TA; Il'ina IuV; Sotnikova TI; Rybakova MK
Klin Med (Mosk); 2004; 82(11):15-20. PubMed ID: 15656392
[TBL] [Abstract][Full Text] [Related]
25. Trimetazidine: the future of cardiac function?
Di Napoli P; Taccardi AA
Future Cardiol; 2009 Sep; 5(5):421-4. PubMed ID: 19715405
[No Abstract] [Full Text] [Related]
26. Meeting the challenge of chronic ischaemic heart disease with trimetazidine.
Marzilli M; Affinito S
Coron Artery Dis; 2005 Nov; 16 Suppl 1():S23-7. PubMed ID: 16340400
[TBL] [Abstract][Full Text] [Related]
27. The metabolic treatment of coronary artery disease and heart failure.
Di Napoli P
Curr Pharm Des; 2009; 15(8):826. PubMed ID: 19275645
[No Abstract] [Full Text] [Related]
28. [Correction of episodes of transitory myocardial ischemia with trimetazidine in patients with ischemic heart disease combined with type 2 diabetes mellitus].
Petriĭ VV; Mikova NV; Makolkin VI
Kardiologiia; 2007; 47(7):22-5. PubMed ID: 18260890
[TBL] [Abstract][Full Text] [Related]
29. Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure.
Fragasso G; Perseghin G; De Cobelli F; Esposito A; Palloshi A; Lattuada G; Scifo P; Calori G; Del Maschio A; Margonato A
Eur Heart J; 2006 Apr; 27(8):942-8. PubMed ID: 16510466
[TBL] [Abstract][Full Text] [Related]
30. The potential benefits of trimetazidine in patients with diabetes and ischemic cardiomyopathy.
Korantzopoulos P; Kountouris E; Siogas K; Galaris D
Am Heart J; 2004 Dec; 148(6):e31; author reply e32. PubMed ID: 15632868
[No Abstract] [Full Text] [Related]
31. [Treating ischemic heart disease by pharmacologically improving cardiac energy metabolism].
Lopaschuk GD
Presse Med; 1998 Dec; 27(39):2100-4. PubMed ID: 9893703
[TBL] [Abstract][Full Text] [Related]
32. [Trimetazidine in the Treatment of Chronic HeartFailure].
Zhirov IV; Osmolovskaya YF; Tereshchenko SN
Kardiologiia; 2016 Jan; 56(1):79-85. PubMed ID: 28294737
[TBL] [Abstract][Full Text] [Related]
33. Trimetazidine improves myocardial perfusion and left ventricular function in ischemic left ventricular dysfunction.
Feola M; Biggi A; Francini A; Leonardi G; Ribichini F; Ferrero V; Uslenghi E
Clin Nucl Med; 2004 Feb; 29(2):117-8. PubMed ID: 14734913
[No Abstract] [Full Text] [Related]
34. Trimetazidine and reduction in mortality and hospitalization in patients with ischemic dilated cardiomyopathy: a post hoc analysis of the Villa Pini d'Abruzzo Trimetazidine Trial.
Di Napoli P; Di Giovanni P; Gaeta MA; Taccardi AA; Barsotti A
J Cardiovasc Pharmacol; 2007 Nov; 50(5):585-9. PubMed ID: 18030070
[TBL] [Abstract][Full Text] [Related]
35. The role of metabolic therapy with trimetazidine in effort tolerance in patients with ischemic heart disease.
Suljić U; Prnjavorac B; Bego T; Malenica M; Dujić T; Prnjavorac I; Čaušević A; Šaranović L
Med Glas (Zenica); 2018 Aug; 15(2):109-114. PubMed ID: 30047538
[TBL] [Abstract][Full Text] [Related]
36. Current Clinical Evidence of Trimetazidine in the Management of Heart Disease in Patients with Diabetes.
Mahajan S; Mahajan AU
J Assoc Physicians India; 2020 Nov; 68(11):46-50. PubMed ID: 33187037
[TBL] [Abstract][Full Text] [Related]
37. Effects of trimetazidine on myocardial perfusion and the contractile response of chronically dysfunctional myocardium in ischemic cardiomyopathy: a 24-month study.
El-Kady T; El-Sabban K; Gabaly M; Sabry A; Abdel-Hady S
Am J Cardiovasc Drugs; 2005; 5(4):271-8. PubMed ID: 15984909
[TBL] [Abstract][Full Text] [Related]
38. Trimetazidine: a meta-analysis of randomised controlled trials in heart failure.
Gao D; Ning N; Niu X; Hao G; Meng Z
Heart; 2011 Feb; 97(4):278-86. PubMed ID: 21134903
[TBL] [Abstract][Full Text] [Related]
39. Angina, myocardial hibernation and trimetazidine.
Jackson G
Int J Clin Pract; 1997 Sep; 51(6):347. PubMed ID: 9489058
[No Abstract] [Full Text] [Related]
40. [Possibilities of myocardial cytoprotection in complex treatment of patients with chronic heart failure].
Vasiuk IuA; Iushchuk EN; Shkol'nik EL; Khadzegova AB; Vit'ko NK; Vakhromeeva MN
Kardiologiia; 2006; 46(11):48-56. PubMed ID: 17159882
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
